BIBF 1120 in Recurrent Glioblastoma Multiforme

Phase 2

Completed

• Conditions: Recurrent Glioblastoma

• Registration Number: NCT01251484
• Lead Sponsor: Ulrik Lassen

Brief Summary

VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is often associated with remote metastases. BEV may stop the growth of tumor cells by blocking blood flow to the tumor. Cediranib, a pan-VEGF inhibitor has shown promising results in recurrent GBM.

VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to BIBF-1120 in such circumstances may open a new treatment option in GBM. In additional, recurrent glioblastomas have an extremely poor prognosis, so innovative therapies are needed.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-12-01
• Study First Submitted QC: 2010-12-01
• Study First Posted: 2010-12-02
• Study Start: 2011-01
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Status Verified: 2012-10
• Last Update Submitted: 2012-10-03
• Last Update Posted: 2012-10-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Response rate	Response evaluation every 8 weeks	MacDonald criteria

Secondary Outcome Measures

Name	Time	Method
Adverse events	Assessed every 2 weeks	CTCAE version 4.0

Trial Locations

Locations (1)

Rigshospitalet; 🇩🇰 Copenhagen, Denmark